查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1456980

全球体外诊断市场 - 2024 年至 2029 年预测

Global In Vitro Diagnostics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年，全球体外诊断市场价值为918.31亿美元，预计预测期内复合年增长率为6.17%，到2029年市场总规模将达1396亿美元。

体外诊断是对从人体采集的样本（例如血液或组织）进行测试，以诊断疾病和其他状况。它还可用于追踪一个人的整体健康状况，以帮助治疗、治癒或预防疾病。这些测试可以在实验室、医疗机构或家中进行。测试本身可以在各种设备上执行，从简单的可携式设备到复杂的测试设备。这些测试使临床医生能够准确诊断患者并提供适当的治疗。

全球 IVD 市场正受益于对照护现场IVD 需求的不断增长。新推出的体外诊断药物因其易于使用且高效而受到医疗保健专业人员的欢迎。市面上也有很多市售的诊断套件，例如血糖监测套件。这些套件受到老年人的青睐，因为它们可以最大限度地减少去医院的次数。

市场驱动因素：

  • 慢性病和感染疾病的盛行率以及人口老化：

已开发市场和新兴市场不断增长的老年人口将对体外诊断市场产生积极影响。随着世界人口老化的迅速增加，与老龄化相关的疾病的盛行率预计将急剧上升。世界其他已开发国家的老年人口也在增加。例如，日本的老年人口与劳动人口的比例最高，其次是德国。据美国医学会称，到2030年，65岁以上的人中60%将患有多种慢性病。因此，随着老年人口的增加，全球各种疾病的盛行率预计将会增加。这被认为是体外诊断药物市场扩张的主要驱动力。

市场限制因素：

  • 逆赎回

报销不足是IVD市场扩张的主要障碍。几年前，美国医疗保险改变了多种体外诊断（包括分子诊断）的报销方式。一些分子病理学测试没有自己的医疗通用程序编码系统 (HCPCS) 代码，而是使用未发布的代码申请。在这些情况下，医疗保险行政承包商 (MAC) 会为其当地管辖区设定付款金额。此类变化可能会损害美国分子和基因检测产业并限制 IVD 市场的成长。

按地区

预计在预测期内，北美将成为体外诊断市场最大的区域市场，并且由于其不断发展的医疗保健系统和患者医疗保健意识的提高，预计该市场将继续保持这一地位。促进市场成长的其他因素包括设备的可用性、如何使用设备的知识的增加以及大量患有各种慢性疾病的人口。推动体外诊断市场扩张的另一个因素是北美存在大量主要企业。此外，由于医疗保健成本上升和糖尿病盛行率上升，预计亚太地区在预测期内将以最高成长率扩张。此外，大量需要体外诊断药物（IVD）测试的慢性疾病患者也促进了亚太市场的成长。

主要进展：

  • 2023 年 5 月 - Thermo Fisher Scientific 和辉瑞将为 30 多个国家（包括拉丁美洲、非洲、中东和亚洲）的肺癌和乳癌患者提供基于次世代定序(NGS) 的试验的现场访问。规模。该合作伙伴关係旨在将快速 NGS 测试带到更接近患者护理点的分散实验室。 Thermo Fisher 将确定使用其 NGS 技术的当地实验室，并确保它们拥有必要的基础设施、训练有素的员工和品管措施。辉瑞致力于为患者提供负担得起的 NGS 检测服务，并提高医疗保健提供者对先进检测的认识。
  • 2023 年 5 月 - 西门子 Healthineers 推出了 Atellica Hema 570 分析仪和 Atellica Hema 580 分析仪，这两种大容量血液学检测系统可消除血液学检测的工作流程障碍。这些分析仪执行全血球计数 (CBC)，这是实验室最常执行的诊断测试之一。它具有直觉的介面、自动化、连接性和基于规则的整合测试，可有效解释复杂的患者结果。这些解决方案可满足大批量血液学检测的需求，并确保包含关键资讯。
  • 2023 年5 月- 全球女性健康先驱Hologic Inc.（纳斯达克股票代码：HOLX）宣布新近入选的NFL 角卫Kelly Ringo 与其母亲、乳腺癌倖存者Tralee Lingo 建立合作关係。 。在美国，女性被诊断出罹患乳癌的频率较高。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球体外诊断市场：依技术分类

  • 介绍
  • 免疫检测
  • 分子诊断
  • 血液学
  • 其他的

第六章体外诊断的全球市场：依应用分类

  • 介绍
  • 感染疾病
  • 自体免疫疾病
  • 药检
  • 肿瘤学
  • 其他的

第七章 全球体外诊断市场：依最终使用者分类

  • 介绍
  • 诊断实验室
  • 医院和诊所
  • 研究所

第八章全球体外诊断市场：依地区划分

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Roche Diagnostics
  • Plasmatec
  • Vitro Bio
  • Omega Diagnostics Group PLC & Technologien GmbH
  • DST Diagnostische Systeme
  • SD Biosensor
  • Abbott Diagnostics
  • Meril Diagnostics
  • NIPPON GENE CO., LTD.
  • Rapid Diagnostics Group of Companies
简介目录
Product Code: KSI061611494

The global in-vitro diagnostics market was valued at US$91.831 billion in 2022 and is expected to grow at a CAGR of 6.17% over the forecast period to reach a total market size of US$139.600 billion by 2029.

In-vitro diagnostics are tests performed on samples obtained from the human body, such as blood or tissue, to diagnose illnesses or other conditions. They can also be used to track a person's general health status to assist in curing, treating, or preventing diseases. These tests can be carried out at labs, healthcare institutions, or even at home. The tests themselves may be carried out on a wide range of equipment, from simple portable devices to sophisticated laboratory gear. They enable clinicians to accurately diagnose patients and work to provide suitable treatments.

The global IVD market has benefited from increased demand for point-of-care IVD equipment. The newly released IVD instruments and devices are simple to use and extremely efficient, which has increased their appeal among healthcare practitioners. There are also numerous over-the-counter diagnostic kits on the market, such as glucose monitoring kits. The elderly prefer these kits since they minimize hospital visits.

MARKET DRIVER:

  • Increased prevalence of chronic and infectious diseases, as well as an aging population:

The growing elderly population in both developed and developing regions would have a positive impact on the IVD market. The prevalence of age-related disorders is projected to rise dramatically as the world's aging population grows rapidly. Geriatric populations are likewise substantial and rising in other industrialized economies across the world. Japan, for example, has the highest ratio of the elderly population to the productive population, followed by Germany. According to the American Medical Association, by 2030, it is expected that 60% of people aged 65 and over will have more than one chronic disease. Therefore, the global prevalence of different disorders is anticipated to rise as the geriatric population grows. This is regarded as a major driver for IVD market expansion.

MARKET RESTRAINT:

  • Unfavourable reimbursement

Inadequate reimbursement is a significant roadblock to the IVD market expansion. A few years ago, Medicare in the United States changed the way it reimbursed several IVD tests, including molecular diagnostics. Some molecular pathology tests don't have their own Healthcare Common Procedure Coding System (HCPCS) codes, so they're charged using unlisted codes instead. Medicare Administrative Contractors (MACs) set a payment amount for their local jurisdictions in such instances. These changes are likely to hurt the molecular and genetic testing industry in the United States, thus limiting the IVD market's growth.

By Geography

North America is projected to be the largest regional market for in vitro diagnostics during the forecast period, and it is likely to continue to do so due to its well-developed healthcare system and growing healthcare awareness among patients. Other factors that contribute to the market's growth include the accessibility of devices, increased knowledge about their usage, and the existence of a significant number of populations suffering from different chronic conditions. Another factor driving the in vitro diagnostics market expansion is the presence of a large number of prominent companies in North America. Furthermore, due to an increase in healthcare expenditure and the incidence of diabetes in the area, Asia-Pacific is anticipated to expand at the highest rate throughout the projection period. Possible factors, such as the large population of patients with other chronic illnesses that necessitate IVD testing, also contribute to the Asia-Pacific market's growth.

Key Development:

  • May 2023- Thermo Fisher Scientific and Pfizer have agreed to expand local access to next generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries, including Latin America, Africa, the Middle East, and Asia. The collaboration aims to bring rapid NGS testing to decentralized labs closer to patients' treatment sites. Thermo Fisher will identify local labs using its NGS technology, ensuring they have the necessary infrastructure, trained staff, and quality control measures. Pfizer will work to enable affordable patient access to NGS tests and raise healthcare provider awareness of advanced testing.
  • May 2023- Siemens Healthineers has launched two high-volume hematology test systems, the Atellica Hema 570 Analyzer and the Atellica Hema 580 Analyzer, which remove workflow barriers in hematology testing. These analyzers perform complete blood counts (CBC), which are among the most performed diagnostic tests in laboratories. They offer intuitive interfaces, automation, connectivity, and integrated rules-based testing for efficient interpretation of complex patient results. These solutions address the need for high-volume hematology testing and deliver critical information reliably.
  • May 2023- A global pioneer in women's health, Hologic Inc. (Nasdaq: HOLX) announced a collaboration with NFL cornerback Kelee Ringo, who was recently drafted, and his mother Tralee Hale, a breast cancer survivor, to raise awareness among women about the significance of making yearly mammograms and other critical health screenings a priority. In the United States, women are more frequently diagnosed with breast cancer.

Market Segmentation

By Technique

  • Immunoassay
  • Molecular Diagnostics
  • Hematology
  • Others

By Application

  • Infectious diseases
  • Autoimmune diseases
  • Drug Testing
  • Oncology
  • Others

By End-User

  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Research Laboratories and Institutes

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

  • 5.1. Introduction
  • 5.2. Immunoassay
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Molecular Diagnostics
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Hematology
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Infectious diseases
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Autoimmune diseases
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Drug Testing
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Oncology
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Hospitals and Clinicals
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Research Laboratories and Institute
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technique
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Technique
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Technique
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Technique
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Technique
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Roche Diagnostics
  • 10.2. Plasmatec
  • 10.3. Vitro Bio
  • 10.4. Omega Diagnostics Group PLC & Technologien GmbH
  • 10.5. DST Diagnostische Systeme
  • 10.6. SD Biosensor
  • 10.7. Abbott Diagnostics
  • 10.8. Meril Diagnostics
  • 10.9. NIPPON GENE CO., LTD.
  • 10.10. Rapid Diagnostics Group of Companies